Navigation Links
Lungs respond to hospital ventilator as if it were an infection
Date:7/18/2012

COLUMBUS, Ohio - When hospital patients need assistance breathing and are placed on a mechanical ventilator for days at a time, their lungs react to the pressure generated by the ventilator with an out-of-control immune response that can lead to excessive inflammation, new research suggests.

While learning that lungs perceive the ventilation as an infection, researchers also discovered potential drug targets that might reduce the resulting inflammation - a tiny piece of RNA and two proteins that have roles in the immune response.

Using human cell cultures, Ohio State University researchers determined that mechanical pressures trigger an innate immune response - the same immune response that the body launches to begin its fight against any kind of infection.

The rhythmic pressure of ventilation stimulated the production of pro-inflammatory chemicals by activating proteins called toll-like receptors (TLRs) in lung cells, the research showed.

"We showed that these cells respond to a mechanical force, pressure, as if it were an inflammatory stimulus. They almost perceive it as a bacterial toxin - and they don't like it," said Samir Ghadiali, associate professor of biomedical engineering at Ohio State and co-lead author of the study. "We didn't know until this study how we could possibly turn off that type of mechanically induced inflammation. Essentially what we found are two things that may help: microRNAs and two TLRs in the innate immunity pathway."

The job of TLRs is to recognize distinctive characteristics of pathogens and send out signals to activate other players in the immune system. This response persists during ventilation even with no pathogen present, and the prolonged inflammation can lead to organ failure. Acute lung injuries requiring mechanical ventilation lead to more deaths annually than do breast cancer and prostate cancer combined.

The study also suggested that at least one tiny piece of RNA - called a microRNA - is influential in this immune response because its behavior regulates the activation of the toll-like receptor proteins. The findings suggest that manipulating levels of either the microRNA or TLRs could be the basis for potential new treatment options for acute lung injury that requires ventilation.

This study appears online and is scheduled for future print publication in the Journal of the Federation of American Societies for Experimental Biology (FASEB Journal).

The study has clinical relevance as well as an influence on the big picture of the field of mechanotransduction - the study of how a mechanical force gets changed into a chemical stimulus inside the body. Mechanics play a role in many disease processes, including hardening of the arteries, other cardiac disorders, kidney problems, emphysema and chronic obstructive pulmonary disease, and cancer.

"This work suggests that there may be a ubiquitous inflammatory mechanism that cells have to respond to anything they perceive as a danger," Ghadiali said. "At least in the lung, we now know the innate immunity pathway plays an important role, and this study showed that a mechanical force gets converted into cytokine production through this well-known pathway."

Ventilators are used on patients in intensive care units who are suffering from a variety of conditions that lead to acute respiratory distress syndrome; these include pneumonia, bacterial or viral infections, trauma and sepsis.

Scientists have known for more than a decade that mechanical ventilation causes inflammation in the lungs that lingers after an acute illness has been cleared, but they have had a hard time figuring out why the lungs respond in this way.

Research attempts to reduce lung damage by altering the force of the ventilation pressure, surface tension or breathing rhythm haven't worked out, said Ghadiali, also an investigator in Ohio State's Davis Heart and Lung Research Institute. So his team, co-led by Patrick Nana-Sinkam, associate professor of internal medicine, sought to determine if there might be another way to regulate lung inflammation in ventilated patients.

The researchers first characterized inflammatory effects of mechanical pressure in experiments using human small airway cells from deep inside the lungs, where ventilation pressure tends to do the most damage.

These tests showed that as little as four hours of exposure to ventilation pressure and breathing rates that mimic the clinical environment raised levels of three proinflammatory cytokines, which are chemical messengers that promote an inflammatory response.

"The cells keep secreting compounds to recruit the immune system to fight an infection, but there is no infection. It's a response we don't want," Ghadiali said.

The scientists then tested these same cells to examine what role microRNAs (miRs) might have in the lung's inflammatory response to ventilation. Using powerful computers to screen the cells for which miRs responded to ventilation pressure and cyclic breathing patterns, they identified a clear target for more study: a microRNA known as miR-146a. This microRNA's activation increased in the cells as experimental levels of cyclic ventilation pressure increased.

MicroRNAs are small pieces of RNA that bind to messenger RNA, which contains the instructions for building proteins in the process of gene expression. When that connection is made, however, the microRNA has an inverse relationship to its target protein, meaning an overexpressed microRNA leads to lower levels of the protein that the microRNA regulates.

"We know that these tiny molecules have the ability to regulate fundamental biological processes in disease. However, their role as mediators of mechanically induced inflammation has yet to be explored," Nana-Sinkam said.

The identification of miR-146a led the researchers to explore the role of two toll-like receptor proteins in the inflammatory response to mechanical ventilation. Because miR-146a has been studied for several years, it is known to target two toll-like receptor proteins that in turn are known to regulate production of the proinflammatory cytokines that the lung cells were found to secrete in response to mechanical pressure.

With this relationship established, the researchers tested the effects of manipulating these various players on the lung cells' inflammatory response. Among their key findings: Dramatically driving up levels of miR-146a in human small airway cells under mechanical ventilation conditions lowered the activity of the two TLRs, which in turn led to very little cytokine secretion - meaning inflammation was held at bay.

"So we have a microRNA that we can overexpress that targets the innate immunity pathway and shuts down mechanically induced inflammation," Ghadiali said.

But the miR is not the only potential target, he noted. Therapies could be designed to target the toll-like receptor proteins themselves, as well, to reduce lung inflammation created by both a disease and the ventilation.

The researchers plan to test the effectiveness of experimental drugs that act on these biological targets in upcoming studies on rodents.


'/>"/>

Contact: Samir Ghadiali, (614) 247-1849; Ghadiali.1@osu.edu
Ghadiali.1@osu.edu
614-247-1849
Ohio State University
Source:Eurekalert

Related medicine news :

1. Study Gives First Evidence That Adult Human Lungs Can Regrow
2. Use of Smokers Lungs for Transplant Has Pros, Cons
3. A marker in the lining of the lungs could be useful diagnostic technique for lung cancer screening
4. Depressed Teens Who Respond to Treatment Less Likely to Abuse Drugs
5. Elsevier announces publishing the Journal of Hospitality, Leisure, Sport and Tourism Education
6. Reporting of hospital infection rates and burden of C. difficile
7. Hospitals for Poor May Struggle Further Under Health Care Reform
8. Hospitals in recession-hit areas see uptick in serious cases of child physical abuse
9. Hospitals Often Not Alerted About Incoming Stroke Patients
10. Stroke Patients Hospitalized on Weekends Dont Seem to Do As Well
11. UCLA study to determine if copper surfaces can reduce hospital-acquired infections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... ... April 28, 2017 , ... Ushio America ... lamps offer an instant energy-saving solution for F32T8 fluorescent lamps on most instant-start ... ballasts. These 50,000 hour rated lamps utilize the existing electronic ballast, saving labor ...
(Date:4/28/2017)... Manhattan New york (PRWEB) , ... April 28, ... ... is pleased to announce that Aditya Patel M.D. has joined the revolutionary endoscopic ... fellowship training and board certification in Interventional Pain Medicine. The patented, revolutionary eDiscSculpt ...
(Date:4/28/2017)... Edinburg, Texas (PRWEB) , ... April 28, 2017 , ... ... a plaque in recently to the labor and delivery team at Women’s Hospital at ... generous mothers who give birth at the hospital and decide to donate. , ...
(Date:4/28/2017)... ... April 28, 2017 , ... Early detection and elimination ... safety and minimize the cost of development. In this webinar, sponsored by Molecular ... lines and for cardiac toxicity using induced pluripotent stem cells (iPSCs). , In ...
(Date:4/28/2017)... ... 28, 2017 , ... Bill Howe started his sewer and drain company in ... Howe joined the team, the Bill Howe brand was born and they began cultivating ... giving back to the San Diego community in which they worked, lived and were ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... Texas , April 20, 2017  Vivify Health, ... mobile devices, has been awarded a very significant patent ... via EMRs to continual care via digital health.  This ... key intellectual property and further secures Vivify,s position as ... launched in 2009, was the first company to apply ...
(Date:4/20/2017)... WOONSOCKET, R.I. , April 20, 2017 /PRNewswire/ ... (NYSE: CVS), today unveiled a new store design ... new assortment of healthier food, health-focused products and ... the store to help customers discover new offerings. ... represent the next evolution of the customer experience ...
(Date:4/20/2017)... LUND, Sweden , April 20, 2017 /PRNewswire/ ... OTCQX: NEVPF) ("NeuroVive") today announced positive preclinical ... company,s preclinical compound for non-alcoholic steatohepatitis (NASH), ... NV556 has previously ... STAM™ NASH model. Today, NeuroVive,s scientists present ...
Breaking Medicine Technology: